Ivuxolimab 

Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4⁺ and CD8⁺ T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc^[1][2][3].

Human IgG2 kappa

Human IgG2 kappa, Isotype Control

Human

Ivuxolimab (0.02-2 μg/mL; 6 days) can significantly promote the proliferation of T cells stimulated by anti-CD3/CD28 in the primary CD4⁺ T cell proliferation experiment, and the dual-epitope antibody (such as 11D4-OX.F2) is more active than the single-epitope antibody^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ivuxolimab ((11D4-OX.F2)) (10 mg/kg; intravenous injection; twice a week; 3 weeks) significantly inhibits tumor growth in the mouse CT26 tumor-bearing model without causing significant body weight loss^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

142.72 kDa

2128729-41-7

Liquid

Colorless to light yellow

[Ivuxolimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 kappa

• 
  Immobilized OX40/TNFRSF4 Protein, Human (HEK293, His, HY-P7394) can bind Ivuxolimab. The EC₅₀ for this effect is 20.45 ng/mL.

• [1]. Diab A, et al. A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. Clin Cancer Res. 2022 Jan 1;28(1):71-83.  [Content Brief]

  [2]. Jhajj HS, et al. Facile generation of biepitopic antibodies with intrinsic agonism for activating receptors in the tumor necrosis factor superfamily. bioRxiv [Preprint]. 2023 Dec 12:2023.12.11.571146.  [Content Brief]

  [3]. Merryman RW, et al. A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma. Ann Hematol. 2024 Jan;103(1):185-198.  [Content Brief]